Bendell et al. [54] conducted clinical trials and concluded that LY3023414 achieved sustained partial remission in endometrial cancer patients with phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1) and phosphate and PTEN mutations. This evidence concerns the gene PIK3R1 and endometrial cancer.